[{"orgOrder":0,"company":"Orphelia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Temozolomide","moa":"DNA","graph1":"Undisclosed","graph2":"Phase I","graph3":"Orphelia Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orphelia Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orphelia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Orphelia Pharma","sponsor":"ClinSearch","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Temozolomide","moa":"DNA","graph1":"Oncology","graph2":"Phase I","graph3":"Orphelia Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Suspension","sponsorNew":"Orphelia Pharma \/ ClinSearch","highestDevelopmentStatusID":"6","companyTruncated":"Orphelia Pharma \/ ClinSearch"},{"orgOrder":0,"company":"Orphelia Pharma","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"FRANCE","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"VGB","moa":"Undisclosed","graph1":"Undisclosed","graph2":"Phase I","graph3":"Orphelia Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Oral","sponsorNew":"Orphelia Pharma \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Orphelia Pharma \/ Inapplicable"},{"orgOrder":0,"company":"Orphelia Pharma","sponsor":"Ethypharm","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"FRANCE","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Vigabatrin","moa":"Gamma-amino-N-butyrate transaminase","graph1":"Neurology","graph2":"Approved FDF","graph3":"Orphelia Pharma","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orphelia Pharma \/ Ethypharm","highestDevelopmentStatusID":"15","companyTruncated":"Orphelia Pharma \/ Ethypharm"}]